Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2020
Headcount
4
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Innohale Therapeutics develops inhaled nitric oxide (iNO) delivery solutions for the treatment of respiratory conditions from many etiologies (including COVID-19) and severe lung infections. The technology produces iNO from ambient air, which improves treatment accuracy and reduces costs and logistics burden.
Q&A
- What is the current status of Innohale Therapeutics?
- Innohale Therapeutics is currently inactive and ceased to operate in January 2025.
- What is Innohale Therapeutics' primary focus?
- Innohale Therapeutics develops inhaled nitric oxide (iNO) delivery solutions for treating respiratory conditions and severe lung infections, including COVID-19.
- How many employees does Innohale Therapeutics have?
- Innohale Therapeutics has 1-10 employees.
- When was Innohale Therapeutics founded?
- Innohale Therapeutics was founded in April 2020.
- What is Innohale Therapeutics' primary sector?
- Innohale Therapeutics' primary sector is Health Tech & Life Sciences.
- What is the current product stage of Innohale Therapeutics?
- Innohale Therapeutics is in the R&D product stage.
- What is the current funding stage of Innohale Therapeutics?
- Innohale Therapeutics is in the Pre-Funding stage.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesLife Support
Target customers
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical Equipment
Business model
B2B
Tags
cardiovascularrespiratorydeliverytherapeutics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/72710330 | |
| YouTube | youtube.com/channel/UChyGiP2tkBB1qgsk8ksdM5w |
Identifiers & details
| Founded | 2020-4 |
|---|---|
| Employees (exact) | 4 |
| Status reason | Non Active, Jan 2025 ceased to operate |